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Background: We sought to evaluate the effects of a strong lipophilic statin (pitavastatin) on plaque components
and morphology assessed by transesophageal echocardiography (TEE) and transthoracic echocardiography (TTE),
as well as plaque inflammation assessed by 18 F-fluorodeoxyglucose (FDG) PET/CT in the thoracic aorta
and the carotid artery. Furthermore, we compared the effects of pitavastatin with those of mild hydrophilic
statin (pravastatin).
Methods: We examined atherosclerotic plaques in the thoracic aorta by TEE and those in the carotid artery
by integrated backscatter (IBS)-TTE and PET/CT. We identified the target plaque, where there was macrophage
infiltration and inflammation, by strong FDG uptake in the thoracic aorta and carotid arteries and measured
maximum standard uptake values (max SUV) by PET/CT. We measured the intima-media thickness (IMT) and the corrected
IBS (cIBS) values in the intima-media complex by TEE and TTE at the same site of FDG accumulation by PET/CT.
Results: Patients were randomly divided into two treatment groups: a pitavastatin group (PI group: n =10, 68.4 ±
5.1 years) and a pravastatin group (PR group: n =10, 63.9 ± 11.2 years). The same examinations were performed after
six months at the same site in each patient. We used calculated target-to-background ratio (TBR) to measure max
SUV of plaques and evaluated percent change of TBR. There was no significant difference in low density
lipoprotein-cholesterol, TBR, IMT and cIBS values in plaques at baseline between the PI and PR groups. After
treatment, there was greater improvement in TBR, cIBS values and IMT in the PI group than the PR group.
Conclusions: The pravastatin treatment was less effective on plaque inflammation than pitavastatin treatment.
This trend was the same in the carotid arteries and the thoracic aorta. Pitavastatin not only improved the
atherosis as measured by IMT and cIBS values but also attenuated inflammation of plaques as measured by
max SUV at the same site. The present study indicated that pitavastatin has stronger effects on the regression
and stabilization of plaques in the thoracic aorta and carotid arteries compared with pravastatin.
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HMG-Co-A reductase inhibitor drugs (statins) reduce
the mortality of myocardial infarction and stroke, and
prevent the progression of atherosclerosis [1,2]. More-
over, it is well known that statins have pleiotropic effects
and there are many reports on these effects [3,4]. We
previously reported that ultrasound integrated backscat-
ter (IBS) can discriminate tissue characteristics of carotid
plaques, and IBS values of carotid media were correlated
with arterial stiffness and the degree of fragmentation of
elastic fiber in carotid media [5,6]. Using the IBS tech-
nique, we also reported that pitavastatin improved ath-
erosclerotic changes in the media of the thoracic aorta
[7]. Although there have been several studies that exam-
ine the effects of statins on atherosclerotic plaque in-
flammation or plaque volume, there are few studies that
examined both morphologic and anti-inflammatory ef-
fects of statins on atherosclerotic lesions.
18 F-fluorodeoxyglucose (FDG) is able to accumulate
in plaque macrophages [8]. FDG-positron emission tom-
ography (PET) imaging of atherosclerotic plaques can be
clinically used to assess the severity of inflammation in
plaques and is highly reproducible [9-11]. Previous stud-
ies demonstrated that simvastatin attenuated 18 F-FDG
uptake in carotid plaques and decreased the standard-
ized uptake values (SUVs), and atorvastatin also reduced
18 F-FDG uptakes in atherosclerotic plaques [12,13].
Statins are pharmacologically divided into hydrophilic
and lipophilic agents. Furthermore, it has been suggested
that the strength of pleiotropic effects may vary depend-
ing on a statin’s characteristics. However, there have
been few studies that have directly compared hydrophilic
and lipophilic statins. The purpose of the present study
was (1) to evaluate the effects of a strong lipophilic statin
(pitavastatin) on plaque components and morphology
assessed by IBS transesophageal echocardiography (TEE),
as well as plaque inflammation assessed by 18 F-FDG
positron emission tomography/computed tomography
(PET/CT) in the carotid artery and thoracic aorta, and (2)




Patients who satisfied the following criteria were enrolled
in the present study: 1) patients with hyperlipidemia [total
cholesterol ≥220 mg/dl and/or low density lipoprotein
(LDL) cholesterol ≥140 mg/dl, as defined by the Japan
Atherosclerosis Society] or who needed lipid lowering
therapy with statin based on the Japanese guidelines for
the prevention of atherosclerotic disease (1–2 coronary
risk factors: an LDL cholesterol ≤140 mg/dl; 3–4 cor-
onary risk factors: an LDL cholesterol ≤120 mg/dl; or
a history of ischemic heart disease despite an LDLcholesterol ≤100 mg/dl) and had no treatment with sta-
tins in the six months before enrollment, 2) patients with
a high risk of atherosclerosis such as a severe plaque ob-
served in the aorta or a carotid artery by past examination
using CT or ultrasound, an aortic calcification observed
through a chest x-ray, or metabolic syndrome, and 3) pa-
tients who required TEE due to atrial fibrillation or valvu-
lar heart disease. Patients were excluded if they had active
infectious disease, poorly controlled diabetes, renal dys-
function or cancer found previously.
Study protocol
This was a prospective, randomized and comparative
study called EPICENTRE study (Anti-inflammatory and
Morphologic Effects of Pitavastatin on Carotid Arteries and
Aorta Evaluated by Integrated Backscatter Trans-esophageal
Ultrasound and PET/CT).
Patients were randomly divided into two groups: a
pitavastatin treatment group (PI group: 2 mg/day), and a
pravastatin treatment group (PR group: 10 mg/day). The
dose of each statin (2 mg/day of pitavastatin and 10 mg/day
of pravastatin) is intermediate dose in Japan. They each re-
ceived treatment for six months, and the same examina-
tions were performed after treatment at the same site in
each patient. Blood biochemical examination was also
conducted to assess lipid profile, glucose metabolism and
the side effects of each medicine before and after treat-
ment. This study protocol was approved by the ethics
committee of our institution. Written informed consent
was obtained from all enrolled patients.
PET/CT image acquisition and analysis
PET/CT images were obtained using methods as described
in a previous study [5,7-10]. Patients were injected with
3.7 MBq /kg (0.1 mCi /kg) of 18 F-FDG intravenously. The
injection was given after fasting for at least 8 hours. After
one hour, two-dimensional whole-body PET/CT imaging
was performed using a PET/CT scanner (Discovery ST
Elite Performance, GE Medical Systems, Milwaukee, WI).
This system can obtain PET and CT images (4.25-mm slice
thickness) simultaneously. CT scan was performed for at-
tenuation correction and PET images were reconstructed
using iteration algorithm (128 × 128 pixel matrix). Images
were obtained over 24 minutes. 18 F-FDG uptake was
measured using a workstation (XTREX VIEW, J-MAC sys-
tem, Japan).
At baseline, we manually found two regions that had a
strong intensity of 18 F-FDG uptake in the thoracic aorta
and carotid arteries in each patient and we defined them
as target plaques. A region of interest (ROI) was placed on
the target plaque as a spherical region 10 mm in diameter.
We measured maximum SUV (max SUV) of the ROI and
considered it as the max SUV of the target plaque. A
target-to-background ratio (TBR) has recently been used
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18 F-FDG uptake by macrophages in inflamed vascular
cells [4]. The TBR was calculated as the max SUV of tar-
get plaques divided by the mean SUV of blood which was
measured in the right atrium. We were able to find target
plaque easily after treatment using the distance from sig-
nificant landmarks on PET/CT images (e.g., calcification
of arterial wall, corpus vertebrae and bifurcations of an ar-
tery). The analyses of PET/CT were conducted by one
radiologist and one cardiologist, who were blinded to the
patients’ treatment assignment. The average of two mea-
surements was used for the analysis. After six months later,
we selected the same region as that selected at baseline by
refereeing CT images.
Transesophageal echocardiography and conventional
ultrasonography
TEE and conventional ultrasonography of carotid arter-
ies were performed to measure intima-media thickness
(IMT) and the corrected IBS (cIBS) values in the intima-
media complex of the target plaques within two weeks
after PET/CT. The IBS values in the intima-media com-
plex were corrected by subtracting the IBS values in the
tunica externa as follows [14]:
cIBS ¼ IBS values in the aortic wall
− IBS values in the tunica externa:
TEE was performed with an ultrasonic imaging system
(SONOS 5500, Philips Medical Systems, Andover, MA,
USA) and a 4–7 MHz multi-plane transducer with a
7.4 mm diameter “pediatric probe” (T6207, Philips Medical
Systems, Andover, MA, USA) in the echocardiography la-
boratory by an operator who was blinded to the patients’
treatment assignment. The oropharynx was anesthetized
with lidocaine before esophageal intubation. After the car-
diac examination, the transducer was rotated in a posterior
direction to obtain aortic images. The cIBS values in the
intima and media of a target plaque and the intima-media
thickness (IMT) at the same site were measured. The dis-
tance between the target plaque and the bifurcation of the
left subclavian artery was measured by counting slices of
CT, and target plaques were anatomically detected by TEE.
If there was a characteristic calcification near the target
plaque, it was also recorded for use as a reference point.
The plaque was detected by this method with high repro-
ducibility. Conventional ultrasound images and cIBS values
of the carotid arteries were easily acquired at the same
time using the same ultrasonic imaging system and a 3–
11 MHz linear-array transducer.
We calculated average IMT and cIBS values of 5 slices
spaced at-1 mm intervals around the target plaques. We
detected two target plaques from thoracic aorta and two
target plaques from right and left carotid arteries in
each patient.Measurement of c-IBS
IBS analysis was performed with a software package
“Acoustic Densitometry” with the SONOS 5500. In this
system, cIBS values are calculated as the average power
of the ultrasonic backscattered signal from the region-
of-interest (ROI) and represent the tissue characteristics.
When measuring IBS values of plaques, ROIs were set
on just the inner side of the tunica externa. The ROIs
(21 × 21 pixels, 1.1 × 1.1 mm) placed at this site covered
only intimal plaques.
The method of measuring IBS values was the same we
previously reported [13]. We calculated averaged IMT
and cIBS of 5 slices at 1-mm intervals around the target
plaque.
Statistical analysis
Data are expressed as the mean ± one standard deviation
or the number of patients (percentage). The normality of
distribution was tested using the Kolmogorov-Smirnov
test. The significance of the differences between groups
that were normally distributed and had similar variances
was tested by an unpaired Student’s t test. Otherwise, a
Mann–Whitney U test was used to compare the differ-
ence between groups. Categorical data were summarized
as percentages and compared using a Chi-square test or
Fisher exact test. The relationships between the change
of lipid profile and the change of TBR were tested for
significance by linear regression analysis. All statistical
analyses were performed using Stat View version 5.0
(SAS Institution Inc., Cary, NC, USA). A p-value < 0.05
was considered significant.
Results
Patients baseline characteristics and biochemical
parameters
We enrolled 24 patients in the present study. One pa-
tient dropped out voluntarily. Three patients were ex-
cluded because of worsening diabetes, active infectious
disease in the follow-up period and an incidental detec-
tion of pancreatic cancer on the first PET/CT. Finally 20
patients were examined (PI group: n =10, 68 ± 5 years;
PR group: n =10, 64 ± 11 years). Baseline clinical charac-
teristics of the patients are shown in Table 1. There were
no significant differences in age, height, body weight,
underlying disease and smoking rates between the PI
and PR groups at baseline.
Baseline biochemical measurements in both groups
are shown in Table 2. There were no significant differences
in lipid level, liver-associated enzymes, creatinine phos-
phokinase and high-sensitive C-reactive protein (hs-CRP)
between the two groups. There were also no differences
between the two groups in other baseline parameters,
such as cIBS values, IMT and TBR, also showed no signifi-
cant difference between the two groups (Table 1). No






Age, year 68 ± 5 64 ± 11 0.26
Man, n (%) 7 (70) 8 (80) >0.99
Height, cm 161.3 ± 6.1 162.5 ± 11.3 0.78
Body weight, kg 65.0 ± 9.1 63.5 ± 10.6 0.73
Main history, n (%)
Hypertension 5 (50) 5 (50) >0.99
Diabetes mellitus 4 (40) 2 (20) 0.36
Smoking, n (%) 6 (60) 5 (50) 0.67
Valvular heart disease 3 (30) 2 (20) 0.63
Medications, n (%)
ARBs or ACEIs 2 (20) 5 (50) 0.18
Beta-blockers 3 (30) 3 (30) >0.99
Ca channel blockers 4 (40) 3 (30) 0.67
ARBs: angiotensin II receptor blockers, ACEIs: angiotensin-converting enzyme
inhibitors, Ca: calcium.
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of liver-associated enzymes (3 times upper limit of normal)
or myositis. There were no differences in baseline under-
lying diseases and were no serious cardiovascular events
including myocardial infarction, unstable angina, or death
in either group during the follow-up period.
Changes after 6 months of statin therapy
After 6 months, total cholesterol and LDL-cholesterol in
the PR group were decreased from 225 ± 21 to 185 ±
16 mg/dl and from 142 ± 24 to 103 ± 18 mg/dl, respectively.
The total cholesterol and LDL-cholesterol in the PI group
significantly decreased from 202 ± 67 to 154 ± 22 mg/dlTable 2 Laboratory parameters
Pitavastatin
Baseline After
Total cholesterol, mg/dl 202 ± 67 154 ±
LDL cholesterol, mg/dl 150 ± 21 80 ± 1
HDL cholesterol, mg/dl 52 ± 12 52 ± 1
Triglyceride, mg/dl 134 ± 35 107 ±
AST, IU/l 28 ± 13 26 ± 5
ALT, IU/l 27 ± 17 25 ± 9
γ-GTP, IU/l 34 ± 19 38 ± 2
CK, IU/l 77 ± 31 85 ± 2
High-sensitive CRP, μg/l 2,883 ± 4,176 3,581 ±
Hemoglobin A1c, % 5.8 ± 0.8 5.9 ± 0
Insulin, μU/ml 7.0 ± 4.7 6.7 ± 3
LDL: low density lipoprotein, HDL: high density lipoprotein, AST: aspartate aminotra
phosphokinase, *p < 0.05 vs baseline, †p < 0.05 vs pravastatin.and from 150 ± 21 to 80 ± 16 mg/dl, respectively. There
was no significant difference in hs-CRP at baseline or six
months, or in the change from baseline to six months be-
tween the two groups, because there were relatively large
variances of the data. There were no significant alterations
in glucose metabolism between baseline and after 6 months
in the two groups (Table 2).
The TBRs of the plaques were significantly decreased
from 1.29 ± 0.22 to 1.04 ± 0.23 in the PI group, whereas
TBRs did not decrease in the PR group (from 1.19 ± 0.16
to 1.19 ± 0.18). The cIBS values in the intima-media com-
plex of the plaques in the PI group increased significantly
more than those in the PR group (−16.4 ± 5.7 dB to −14.3 ±
4.7 dB and −18.2 ± 3.7 dB to −17.9 ± 4.1 dB, respectively).
The IMT of the plaques in the PI group was significantly
reduced, but the IMT in the PR group increased (2.85 ±
0.76 mm to 2.58 ± 0.63 mm and 2.87 ± 0.72 mm to 3.14 ±
0.7 mm, respectively). There were significant improve-
ments of TBR, cIBS and IMT in the PI group but
there was less effect on these parameters in the PR group
(Figures 1, 2, 3). This trend was the same also in the carotid
arteries and the thoracic aorta (Figure 3). The changes of
TBR and cIBS values between baseline and 6 months were
significantly correlated with the change of LDL cholesterol
(r = 0.65 and r = 0.45, respectively), but not the change of
HDL cholesterol (Figure 1).
Discussion
The present study compared the effects of a strong lipo-
philic statin (pitavastatin) on plaque components and
morphology as well as plaque inflammation. The present
study also demonstrated that statin decreased plaque
volume measured by intima-media thickness and con-
tributed to plaque stabilization measured by cIBS values.
Furthermore, pitavastatin stabilized plaque inflammationPravastatin
6 months Baseline After 6 months
22*† 225 ± 21 185 ± 16*
6*† 142 ± 24 103 ± 18*
1 54 ± 15 55 ± 13
52 167 ± 63 135 ± 71
34 ± 18 32 ± 13
29 ± 15 30 ± 12
8 79 ± 89 76 ± 84
6 95 ± 53 108 ± 63
8,445 1,747 ± 2,239 3,928 ± 5,025
.7 5.4 ± 0.5 5.5 ± 0.4
.5 5.4 ± 2.9 4.7 ± 2.6
nsferase, ALT: alanine aminotransferase, CRP: C-reactive protein, CK: creatinine
Figure 1 Correlation between the changes in each parameter from baseline to 6 months and the changes in low density lipoprotein
cholesterol and high density lipoprotein cholesterol. Red dots indicate pravastatin group and blue dots indicate pitavastatin group.
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carotid artery and the thoracic aorta.
In addition, we demonstrated that the change of cIBS
values and TBR were correlated with the change of LDL
cholesterol, but not with the change of HDL cholesterol.Figure 2 PET: positron emission tomography, TEE: trans-esophageal ech
thickness, cIBS: corrected integrated backscatter.Tahara et al. suggested that attenuation of vascular inflam-
mation may be associated with an increase in HDL choles-
terol rather than with LDL cholesterol in a study using
simvastatin [9]. On the other hand, Ishii H et al. reported
that decreased TBR was correlated with a reduction ofocardiography, TBR: target-to-background ratio, IMT: intima-media
Figure 3 PET/CT and ultrasound parameters, TBR: target-to-background ratio, IMT: intima-media thickness, cIBS: corrected integrated
backscatter, *p < 0.05 vs baseline, †p < 0.05 vs pravastatin.
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correlation between a change of cIBS values and TBR and
a change of LDL cholesterol rather than that of HDL chol-
esterol. In addition, a strong lipophilic statin decreased
LDL cholesterol and changed TBR and cIBS values more
than a mild hydrophilic statin. Other investigators re-
ported that there was a significant correlation between
LDL cholesterol lowering effects and anti-inflammatory
effects [15]. The findings in the present study reinforced
the previous findings.
It is known that high plasma hs-CRP concentrations are
associated with high cardiovascular risk. In addition, hs-
CRP was decreased in diabetic patients treated with pita-
vastatin regardless of a change in serum lipid profile [16].
However, in the present study, we could not establish a re-
lationship in hs-CRP because there were relatively large var-
iances of the hs-CRP. It was speculated that the reasons were
the nonspecificity of hs-CRP and small sample size in the
present study. Actually, arthritis and enteritis were detected
by PET/CT in some enrolled patients in the present study.
It is thought that lipophilic statin diffuses more directly
to vascular endothelial cells and has a stronger pleiotropic
effect than hydrophilic statin [3]. Treatment for six monthsin the present study with a mild hydrophilic statin im-
proved neither TBR nor IBS, and IMT significantly in-
creased from baseline. There was a similar report that
pravastatin resulted in less regression of the carotid artery
IMT than rosuvastatin [17]. The present study suggests
that it is better to use a strong lipophilic statin rather than
a mild hydrophilic statin to prevent or cause regression of
atherosclerosis in the clinical setting.
In the present study, we obtained PET images using rela-
tively short duration (one hour) after the injection of FDG.
There were several studies that employed various durations
between the injection of FDG and PET imaging for the
evaluation of atherosclerotic lesions (1–3 hours) [9,12,18].
Studies that employed long duration between the injection
and imaging aimed to include the change of proper uptake
by macrophages as well as better washout of radioactivity
from the blood pool. Contrary, we aimed to include the
change of the high residual activity in neighboring pixels
due to the short injection-to-imaging time.
Study limitations
There are several limitations of this study. First, the num-
ber of patients in our analysis was small. Our results and
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lation. Second, this study was based on the assumption
that cIBS values of the thoracic aorta reflect the same type
of histological changes indicated by the cIBS values of ca-
rotid artery that have already been validated. Validation
between the cIBS values and tissue components in the
thoracic aorta are required. Third, we did not use Agat-
ston score for the evaluation of atherosclerosis because
the CT protocol was used only for PET attenuation cor-
rection. However, process of progression of calcification is
gradual and not suitable for the relatively acute change by
the effects of statins. Fourth, a small size of the ROI
chosen for PET quantification in the present study may
hinder accurate reproducibility of measurements. Rela-
tively large ROIs should be used to improve the reprodu-
cibility of measurements.
Conclusions
Pitavastatin not only improved atherosis measured by
IMT and the sclerosis measured by cIBS values, but also
attenuated inflammation of plaques at the same site as
measured by max SUV. The present study indicated that
pitavastatin had a stronger effect on regression and
stabilization of plaques in the thoracic aorta compared
with a mild hydrophilic statin.
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